#USA #New York #Securities Fraud #AQST #Daniel Barber

Investor Alert: AQUESTIVE THERAPEUTICS, INC.

A civil lawsuit has emerged involving Aquestive Therapeutics, Inc. (NASDAQ: AQST), with investors being alerted to the possibility of class action claims against the company. Levi & Korsinsky, LLP has announced that their legal team is investigating potential securities fraud related to misrepresented company prospects by CEO Daniel Barber during the class period of June 16, 2025, through January 8, 2026.

Context of the Lawsuit

On January 9, 2026, AQST shares saw a dramatic decrease, losing $2.30, representing a staggering 37% drop in a single trading day. The lawsuit alleges that during this period, Barber may have failed to disclose essential information regarding the company’s products and their regulatory standings, which could be pivotal for investor decision-making. The court has set May 4, 2026, as the deadline for investors who wish to apply for lead plaintiff status.

The Role of Daniel Barber

Daniel Barber has held various executive roles in the company, including CEO, President, and Director. As the principal architect of company communications, he is accused of having both control and authority over the contents of regulatory filings and press releases. The complaint suggests that he had the chance to both prevent misstatements and correct information.

Legal Implications

Under Section 20(a) of the Securities Exchange Act of 1934, individuals who control companies that violate security laws can themselves be held liable. By virtue of his senior role, Barber is alleged to have significant control over business operations and information disclosure, specifically regarding the Anaphylm NDA regulatory timeline.

Barber's position comes with specific law-mandated responsibilities, particularly as dictated by the Sarbanes-Oxley Act, requiring that he personally certifies the accuracy of the financial and operational disclosures made by the company to the SEC. The lawsuit contends that these obligations were neglected, especially highlighting the potential risks and deficiencies in the Anaphylm NDA that Barber was potentially aware of. Consequently, while he assured stakeholders regarding regulatory timelines, he possibly misrepresented facts or omitted vital information pertinent for informed investment decisions.

Investigation Outcomes

Joseph E. Levi, Esq., representing the firm, emphasized the importance of accountability for CEOs in ensuring that their companies' public statements are truthful. He points out that when a corporate officer like Barber attests to the truthfulness of SEC filings and combines that with public statements about the company's direction, shareholders have a legitimate basis to hold accountable through litigation for any alleged inaccuracies.

If you believe you've incurred losses due to misrepresentations by Aquestive, you may wish to consider joining this class action. Interested parties can contact Levi & Korsinsky’s office for more information regarding their potential involvement in the recovery process. The firm has a remarkable pedigree, being recognized as one of the top 50 securities litigation firms, with a history of recovering substantial amounts for shareholders.

Future Considerations

Moving forward, it’s crucial for investors to remain vigilant about their investment decisions and the clarity of information provided by company executives. As this case unfolds, more will be revealed about corporate governance lapses and the significant consequences these can have on company valuations and investor trust. It remains to be seen what the outcomes of this lawsuit will be and how it might affect the future of Aquestive Therapeutics.

For more information or to see whether you qualify for participation in the class action, reach out to Joseph E. Levi, Esq. at (212) 363-7500 or via email at [email protected]